Neurogen suspends Phase II/III insomnia study
This article was originally published in Scrip
Neurogen has suspended dosing in a Phase II/III trial of its lead drug candidate, adipiplon, an investigational insomnia treatment.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.